Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

November 07, 2005 06:00 ET

Swiss Medica Launches Educational and Sampling Programs for Health Professionals

TORONTO, ONTARIO--(CCNMatthews - Nov. 7, 2005) - Swiss Medica, Inc. (OTCBB:SWME) today announced that it has launched a comprehensive educational and sampling program for health professionals including physicians, chiropractors, and pharmacists. The strategy will focus on all three of Swiss Medica's products that are presently available in national drugstores in the United States: O24 Pain Neutralizer, PMS Escape and the newly launched O24 Fibromyalgia.

Swiss Medica's educational program includes:

a) Providing samples and product information at physician continuing medical education conferences.

b) Providing physicians, chiropractors and other health professionals with sampling dispensing units for their offices so that they can offer their patients samples of Swiss Medica's products.

c) Arranging for leading physicians to educate other health professionals about Swiss Medica's safe and effective patented products at medical conferences as well as presenting double-blind studies that highlight the high efficacy of these products.

d) Educating and sampling pharmacists at conferences to educate them on the differentiated and unique attributes of Swiss Medica's products.

e) Direct informational mailers to physicians and other health professionals specializing in the chronic ailments that Swiss Medica's elite products address.

Swiss Medica was present as an exhibitor last week at the American Osteopathic Association national conference in Orlando, Florida. The convention attracted over 6,000 primary care and specialty physicians. There was significant interest in Swiss Medica's elite over-the-counter products and over 600 physicians from across the United States have requested further information on our products and/or sampling units in their medical offices.

Dr. Robert Maurer DO, a senior member of the board of directors of the American Osteopathic College of Rheumatology, after sampling the product personally for a couple of days during the conference in Orlando, was quoted saying " I have had extensive back pain for several months. This product gave me a tremendous amount of relief and comfort. It was easy to apply and with no appreciable side effects. I would highly suggest other pain sufferers try O24 for pain relief."

In addition, Swiss Medica featured its O24 Pain Neutralizer and O24 Fibromyalgia patented, clinically and medically tested all natural products at the American Academy of Pain Management Conference in San Diego in late September and received significant interest in our unique products. We have already shipped over 125 sampling units to physician offices throughout the United States

In addition, the National Fibromyalgia Association will begin in November an integrated communications program with over 10,000 physicians and other health professionals throughout the USA who treat Fibromyalgia. This educational and sampling campaign is being conducted to introduce health professionals to O24 Fibromyalgia, the first clinically-tested product specifically for Fibromyalgia that is available in national pharmacies and the first and only product to receive the National Fibromyalgia Association's Seal of Approval.

"We have found that physicians and other health professionals are eager to learn about Swiss Medica's elite patented over-the-counter alternatives to prescription medications", says Swiss Medica CEO, Raghu Kilambi. "Given the significant side effect concerns with many prescription drugs, health professionals want, more than ever, to offer their patients safe, effective over-the-counter medication for their acute and chronic ailments The response to our products at recent medical conferences and the widespread desire of physicians to offer samples of Swiss Medica's products to their patients is a testament to the growing acceptance of our products by health professionals."

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at , and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit for information on O24 Fibromyalgia and to order the product online.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    Fusion Communications
    Media Contact:
    Dean Mailey
    (604) 218-6767